You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer

FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes

WuXi AppTec awarded EcoVadis gold medal for third year

Suzhou Ribo Life Science submits Phase I Clinical Trial Application for RBD3133 in EU

Roche Diagnostics supplies molecular testing instruments to support Ebola response in the DRC

ABIONYX Pharma partners with OLON to prepare CER-001 for regulatory approval and potential commercial supply

Enliven Therapeutics reaches FDA alignment on relcobatinib (ELVN-001) Phase 3 trial design for previously treated CML

Voyager signs cancer research mission management contract

Pillar Biosciences introduces oncoReveal Myeloid v2 Panel

AbbVie and Genmab report positive results from epcoritamab Phase 3 study in diffuse large B-cell lymphoma

Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting

Moberg Pharma reports new Phase 3 analyses on terbinafine activity in onychomycosis

GE HealthCare to acquire SOFIE Biosciences for USD945m

Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy

CSL and Alentis partner for lixudebart development and commercialisation for rare kidney and liver diseases

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026